November 25, 2019
1 min read

Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Phase 2 study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia. This study is targeting patients with newly diagnosed B-ALL predicted to have an exceedingly poor outcome with conventional chemotherapy, in high-risk first relapse, or in second or greater relapse.